The three randomised clinical studies investigating GLP-1 receptor agonists in overweight or obese women with PCOS Salamun et al., Liu et al., and Nylander et al., constitute the most significant human evidence [28,29,30]. The gene discussed is GLP1R; the disease is polycystic ovary syndrome.